Human Cell-Based Artificial Antigen Presenting Cells for Use in Natural Killer Cell Adoptive Therapy

Natural Killer (NK) cells are critical components of the immune system responsible for tumour recognition and eradication. Recent studies of haematopoietic cell transplantation highlighted the utility of NK cell adoptive therapy used to enhance the graft-versus-leukaemia effect without worsening graft-versus-host disease. However, NK cell adoptive therapy is limited by the fact that it is difficult to prepare clinically adequate numbers of NK cells. Artificial antigen presenting cells have been designed and developed as an off-the-shelf strategy to prime NK cell production in vitro; facilitating the production of adequate cell numbers capable of efficiently engrafting, persisting, and responding to tumours in vivo.